First companies benefit from Maximon's Longevity Co-Investment Fund

Please login or
register
07.10.2021
Maximon team

The newly launched CHF 100 million Fund finances longevity-focussed start-ups founded by Swiss company builder Maximon. The Fund’s first investments include Zug based companies AVEA and Biolytica.

Maximon is the Swiss longevity company builder that empowers entrepreneurs to build impactful, science-based and scalable companies providing healthy ageing and rejuvenation solutions. It identifies the most promising business opportunities in the field of longevity. It operationally works with entrepreneurs to build ventures from scratch by providing proven structures, financing, and a unique and inspiring playground for entrepreneurs.

Two start-ups have already been established as a result. Avea develops science-based and tested longevity supplements, allowing for precise and tailor-made delivery to individuals, ensuring improvements in health and well-being and slowing down ageing. The data-driven health analytics company, Biolytica, aims to make increased healthspan and performance accessible to everyone by combining state-of-the-art health data analytics and personalised longevity programs based on the latest scientific and medical breakthroughs.

The start-ups will receive funding as part of the newly launched CHF 100 million Longevity Co-Investment Fund (LCIF), which finances venture companies established by Maximon. The Fund had its first closing in the founder’s share class at CHF 6 million. The LCIF invests up to CHF 10 million per company, which allows to finance up to 10-12 start-ups in this fast-growing industry over the next four years. The LCIF will remain open for investors for the next 18+ months.

Tobias Reichmuth, Founding Partner at Maximon, states: “Longevity is the new big investment opportunity. There is simply nobody who would not want to age in good health.

Maximon Founding Partner Marc P. Bernegger adds: “The recent progress in extending and enforcing a healthy lifespan is very impressive and creates unique and massive investment opportunities. We already have substantial subscription requests for the Fund’s next closing”.

The Maximon team is responsible for two IPOs, various double and triple-digit exits and has raised more than CHF 2bn investment capital. Maximon has formed a venture building process that bridges the gap between science and business.

(Press release/RAN)

0Comments

More news about

Avea Life AG

Biolytica AG

Company profiles on startup.ch

Avea Life AG

Biolytica AG

rss